--- title: "Swedish Orphan Biovitrum AB (SOBI) stock news and catalysts" url: "https://aibio.space/companies/swedish-orphan-biovitrum/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Swedish Orphan Biovitrum AB news for investors: Sobi is a Stockholm-based rare disease company that sells medicines in haematology, immunology and specialty…" --- Desk view · Opinion · Updated Oct 22, 2026 ## Sobi's growth is real, and the gout bets will decide how well it carries its debt Sobi is growing quickly and has raised its outlook, but it has borrowed to acquire a gout program and faces a chief executive change. The next year depends on the REDUCE 1 data, the pozdeutinurad filing and the NASP resubmission. Read the full desk view aibio.space Investor Rank · Opinion **7** /10 Positive view Revenue grew 29% with raised guidance, but borrowing for gout assets, a delayed NASP resubmission and a CEO departure make execution the key test. - **Technology**: 2/2 - **Odds**: 1/2 - **Balance sheet**: 1/2 - **Risk**: 1/2 - **Momentum**: 2/2 Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank). - **Technology**: **Acquired and licensed portfolio.** Sobi sells haematology, immunology and specialty care medicines and has added gout, lymphoma and lipid programs through deals. - **Odds**: **Mixed.** Pozdeutinurad met its REDUCE 2 endpoint and Tryngolza has a positive CHMP opinion, while NASP needs a manufacturing fix before resubmission. - **Balance sheet**: **Stretched but supported by earnings.** Net debt was SEK 16,126 million on June 30, against second-quarter operating cash flow of SEK 1,912 million. - **Main risk**: **Execution through a leadership change.** The chief executive leaves by January 2027 while gout filings and launches are due. - **Watch next**: Third-quarter report on October 27, 2026, then the Tryngolza European Commission decision expected in Q4. ## Top news on Swedish ## Dates **October 27, 2026** Third-quarter 2026 report, with a call at 15:00 CET [Source](https://www.sobi.com/en/press-releases/invitation-sobis-q3-2026-report-2486533) **Q4 2026** European Commission decision on Tryngolza in severe hypertriglyceridemia [Source](https://www.sobi.com/en/press-releases/sobi-receives-positive-chmp-opinion-tryngolzar-olezarsen-treatment-severe-hypertriglyceridemia-shtg-2488430) **H2 2026** REDUCE 1 Phase 3 data for pozdeutinurad in gout [Source](https://mb.cision.com/Main/14266/4351834/4107642.pdf) **Q1 2027** First patient expected in the lacutamab TELLOMAK-3 Phase 3 study [Source](https://www.sobi.com/en/press-releases/sobi-and-innate-announce-partnership-now-effective-following-completion-closing-conditions-2481658) **By end of January 2027** Chief executive transition, with the board searching for a successor [Source](https://www.sobi.com/en/press-releases/guido-oelkers-step-down-ceo-sobi-beginning-2027-2471868) ## The money Cash and cash equivalents of SEK 1,082 million on June 30, 2026, with net available committed credit facilities of SEK 9,822 million. Net debt was SEK 16,126 million, up from SEK 10,081 million at year-end 2025. [Source](https://mb.cision.com/Main/14266/4375126/4194029.pdf) Q2 2026 revenue of SEK 7,842 million, up 29% at constant exchange rates; first-half revenue of SEK 15,025 million. 2026 outlook is mid- to high-teens revenue growth at constant currency. [Source](https://www.sobi.com/en/press-releases/sobi-q2-2026-report-significant-growth-important-pipeline-progress-2469376) ## Risks on the record - NASP received an FDA complete response letter over manufacturing and contract facility deficiencies, and resubmission is not listed until 2027. [Source](https://mb.cision.com/Main/14266/4375126/4194029.pdf) - Net debt of SEK 16,126 million after the Arthrosi acquisition, with contingent payments of up to USD 550 million for that deal. [Source](https://mb.cision.com/Main/14266/4375126/4194029.pdf) - Chief executive Guido Oelkers is leaving by the end of January 2027 and no successor has been named. [Source](https://www.sobi.com/en/press-releases/guido-oelkers-step-down-ceo-sobi-beginning-2027-2471868) ## Questions investors ask ### What is aibio.space's Investor Rank for Swedish Orphan Biovitrum AB? 7 out of 10, our positive view. Revenue grew 29% with raised guidance, but borrowing for gout assets, a delayed NASP resubmission and a CEO departure make execution the key test. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank) ### What is Sobi's 2026 revenue guidance? As of the July 16, 2026 Q2 report, Sobi expects revenue to grow by a mid- to high-teens percentage at constant exchange rates, up from low double digits. It expects an adjusted EBITA margin in the mid- to high-30s percent of revenue. [Source](https://www.sobi.com/en/press-releases/sobi-q2-2026-report-significant-growth-important-pipeline-progress-2469376) ### Why did the FDA issue a complete response letter for NASP? Sobi said the FDA asked for more data on the manufacturing control strategy of the biological component and for fixes to deficiencies at a contract manufacturing facility. Sobi said the FDA identified no concerns about efficacy or safety that affect approvability. [Source](https://mb.cision.com/Main/14266/4375126/4194029.pdf) ### Did pozdeutinurad succeed in Phase 3? In the REDUCE 2 study, both doses met the primary endpoint. At month 6, 69.2% of patients on 75 mg and 56.6% on 50 mg had serum uric acid below 6 mg/dL, compared with 8.1% on placebo. The second study, REDUCE 1, is expected in the second half of 2026. [Source](https://mb.cision.com/Main/14266/4351834/4107642.pdf) ### What did Sobi agree with Innate Pharma? Sobi pays Innate USD 75 million upfront for exclusive global commercial rights to lacutamab if it gains accelerated approval, with up to USD 40 million in near-term milestones and up to USD 465 million in further milestones. Innate will run the TELLOMAK-3 Phase 3 trial. [Source](https://www.sobi.com/en/press-releases/sobi-enters-strategic-partnership-innate-pharma-license-lacutamab-t-cell-lymphoma-2472935) ### Who is the CEO of Sobi? Guido Oelkers is president and CEO of Sobi. On August 3, 2026, Sobi said he will step down by the end of January 2027 at the latest, and the board has started a search for a successor. [Source](https://www.sobi.com/en/press-releases/guido-oelkers-step-down-ceo-sobi-beginning-2027-2471868) ## Legal and investor matters Checked against Swedish Orphan Biovitrum AB filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026. 1. 2026-08-10 Other Sobi licenses lacutamab from Innate Pharma, paying USD 75 million at closing On 2026-08-10 Sobi and Innate Pharma announced a strategic partnership for lacutamab in cutaneous T-cell lymphoma. Sobi will pay Innate USD 75 million, payable on closing, with up to a further USD 40 million in near-term development milestones and up to USD 465 million related to an option for Sobi to obtain full development rights and to future regulatory and commercial milestones. Sobi will receive exclusive global rights to commercialise lacutamab upon potential accelerated approval. A later Sobi release said the partnership became effective after the applicable antitrust waiting periods expired. [Sobi press release](https://www.sobi.com/en/press-releases/sobi-enters-strategic-partnership-innate-pharma-license-lacutamab-t-cell-lymphoma-2472935) 2. 2026-08-03 Governance Sobi CEO Guido Oelkers to step down by end of January 2027 On 2026-08-03 Sobi announced that CEO Guido Oelkers had told the board he would step down to take up another position outside the company. He will remain in the role until the end of January 2027 at the latest. The board said it would begin a process to secure a structured transition and appoint a new chief executive. [Sobi press release](https://www.sobi.com/en/press-releases/guido-oelkers-step-down-ceo-sobi-beginning-2027-2471868) 3. 2025-12-13 Other Sobi agrees to acquire Arthrosi Therapeutics for USD 950 million upfront On 2025-12-13 Sobi announced a definitive agreement to acquire Arthrosi Therapeutics, developer of the gout drug candidate pozdeutinurad. Sobi will pay USD 950 million in cash upfront plus up to USD 550 million in milestones, funded mainly through debt, including a new credit facility from Handelsbanken and Danske Bank. Sobi announced on 2026-02-09 that it had completed the acquisition. [Sobi press release](https://www.sobi.com/en/press-releases/sobi-acquire-arthrosi-therapeutics-strengthening-pipeline-potential-treatment-gout-2413046) 4. 2025-10-21 Governance Sobi board member Helena Saxon resigns On 2025-10-21 Sobi announced that board member Helena Saxon had resigned her position effective immediately. She had served on the board since 2011 and, according to the release, will be nominated for election to the board of another company serving the healthcare industry. Chairman David Meek thanked her for her contributions. [Sobi press release](https://www.sobi.com/en/press-releases/change-sobi-board-directors-2398510) 5. 2025-10-20 Other Sobi raises 2025 outlook and books SEK 6,612 million Vonjo impairment On 2025-10-20 Sobi raised its 2025 outlook, now expecting low double-digit revenue growth at constant exchange rates and an adjusted EBITA margin in the mid-to-high 30s per cent of revenue. It also recorded an impairment charge of SEK 6,612 million in Q3 2025 on the product and marketing right for Vonjo, which it said did not affect cash flow. It moved its Q3 report forward to 2025-10-20. [Sobi press release](https://www.sobi.com/en/press-releases/sobi-announces-revised-full-year-outlook-and-advances-publication-q3-2025-financial-report-2397851) 6. 2025-07-01 Financing Sobi pays Apellis USD 275 million upfront to cut ex-US Aspaveli royalties by 90% On 2025-07-01 Sobi announced a capped royalty purchase agreement with Apellis Pharmaceuticals under which it reduces its ex-US royalty obligations on Aspaveli (systemic pegcetacoplan) by 90%. Sobi pays USD 275 million upfront and up to USD 25 million in additional milestone payments tied to European Union approvals for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis. [Sobi press release](https://www.sobi.com/en/press-releases/sobi-amend-existing-agreement-apellis-ex-us-royalties-aspavelir-systemic-pegcetacoplan-2349081) 7. 2024-12-11 Governance Sobi EGM elects David Meek as board chair At an extraordinary general meeting on 2024-12-11, Sobi shareholders, in accordance with the nomination committee's proposals, elected David Meek as a new member and chair of the board for the period until the end of the 2025 annual general meeting. [Sobi press release](https://www.sobi.com/en/press-releases/bulletin-sobis-extraordinary-general-meeting-egm-2287025) ## Pipeline | Program | Indication | Stage | |---|---|---| | Pozdeutinurad (AR882, oral URAT1 inhibitor, from Arthrosi) | Gout, including uncontrolled and tophaceous gout | Phase 3; REDUCE 2 met primary endpoint, REDUCE 1 due H2 2026, BLA submission listed for 2027 [Source](https://mb.cision.com/Main/14266/4351834/4107642.pdf) | | NASP (nanoencapsulated sirolimus plus pegadricase) | Uncontrolled gout in adults | FDA complete response letter on manufacturing; resubmission listed for 2027 [Source](https://mb.cision.com/Main/14266/4375126/4194029.pdf) | | Tryngolza (olezarsen, licensed from Ionis outside the US) | Severe hypertriglyceridemia (EU) | Positive CHMP opinion October 16, 2026; European Commission decision expected Q4 2026 [Source](https://www.sobi.com/en/press-releases/sobi-receives-positive-chmp-opinion-tryngolzar-olezarsen-treatment-severe-hypertriglyceridemia-shtg-2488430) | | Lacutamab (anti-KIR3DL2 antibody, from Innate Pharma) | Cutaneous T cell lymphoma, including Sezary syndrome | Phase 3 TELLOMAK-3 to start; first patient expected Q1 2027 [Source](https://www.sobi.com/en/press-releases/sobi-and-innate-announce-partnership-now-effective-following-completion-closing-conditions-2481658) | | Gamifant (emapalumab) | HLH/MAS in Still's disease | Japan decision listed for H2 2026 and Europe decision listed for 2027 [Source](https://mb.cision.com/Main/14266/4375126/4194029.pdf) | | Vonjo (pacritinib) | Myelofibrosis | Phase 3 PACIFICA fully enrolled; data readout listed for 2027 [Source](https://mb.cision.com/Main/14266/4375126/4194029.pdf) | ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OMXSTO:SOBI on TradingView](https://www.tradingview.com/symbols/OMXSTO-SOBI/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/swedish-orphan-biovitrum/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Swedish Orphan Biovitrum AB (SOBI) stock news and catalysts", 2026-10-31, https://aibio.space/companies/swedish-orphan-biovitrum/